The FDA Approved a Drug Without a Clinical Trial. The Real Story Is About What It Didn't Approve.

On March 10, 2026, the Food and Drug Administration quietly approved a decades-old generic vitamin for one of the rarest diseases known to medicine. What should have been a straightforward regulatory action instead became the final chapter of a six-month saga involving presidential promises, a retracted scientific study, a nationwide drug shortage, and desperate families caught between political rhetoric and medical reality.

The Approval

The FDA approved leucovorin calcium — sold under the brand name Wellcovorin — as the first treatment for cerebral folate transport deficiency (CFTD) in adults and children with a confirmed variant in the FOLR1 gene [1]. The condition is estimated to affect approximately 1 in 1 million people, with fewer than 50 cases ever documented worldwide [2].

What makes this approval remarkable is not the drug itself — leucovorin has been available for decades as an inexpensive generic used primarily in cancer treatment — but the regulatory pathway the FDA used to get there. Instead of requiring a randomized clinical trial, the agency based its decision on a systematic review of published literature, including case reports with patient-level information and mechanistic data [3].

In those historical case reports, patients with CFD-FOLR1 who received leucovorin showed a clinical response rate of 87%, with normalization of cerebrospinal fluid 5-MTHF levels — a bioavailable form of folate — in 80% of cases [1]. For a disease this rare, where assembling a trial cohort would be virtually impossible, the literature-based approach represents a pragmatic use of real-world evidence that the FDA has precedent for in ultra-rare conditions [4].

What the FDA Didn't Approve

But the far bigger story is what the FDA declined to do. Despite months of signaling from the Trump administration that leucovorin would become the first FDA-recognized treatment for autism, the agency found insufficient evidence to support that claim [5].

"We don't have sufficient data to say that we could establish efficacy for autism more broadly," a senior FDA official stated on March 10 [6].

The contrast between the September 2025 announcement and the March 2026 reality could not be starker.

The September Promise

On September 22, 2025, President Donald Trump appeared in the Roosevelt Room of the White House alongside FDA Commissioner Dr. Marty Makary and Health and Human Services Secretary Robert F. Kennedy Jr. to announce what they called "significant medical and scientific findings for America's children" [7].

Makary highlighted small studies suggesting that among children with folate deficiency and autism, leucovorin could improve speech for roughly 60%. Administration officials wrote that they were "opening the door to the first FDA-recognized treatment for autism" [7]. Trump himself said the label change "gives hope to the many parents with autistic children that it may be possible to improve their lives" [8].

The announcement came as Kennedy was nearing a self-imposed deadline to determine the cause of autism by September 2025 — a promise he made upon taking office as HHS Secretary [7].

The Prescription Surge and Its Consequences

The political fanfare had immediate, measurable consequences.

Source: GDELT Project

Data as of Mar 11, 2026CSV

According to data published in The Lancet, leucovorin prescriptions for children aged 5 to 17 surged 71% above normal levels in the two-and-a-half months following Trump's September announcement [6]. New prescriptions for leucovorin doubled during this period [8].

The surge created a crisis that rippled through the healthcare system. Cancer patients — the primary users of leucovorin as a rescue agent after high-dose methotrexate chemotherapy and as a modulator of 5-fluorouracil — found themselves competing for a suddenly scarce medication [9]. The American Society of Health-System Pharmacists reported that most leucovorin manufacturers placed their tablets on allocation or backorder, meaning pharmacies could order only limited quantities [9].

Because leucovorin is inexpensive and widely available as a generic, profit margins are thin and fewer manufacturers produce it. When supply depends on only a handful of companies, even modest demand increases can trigger shortages [9]. In December 2025, the FDA took the unusual step of authorizing imports of leucovorin tablets from Canada and Spain to ease the shortfall [9].

Some parents, unable to secure prescriptions, turned to unregulated over-the-counter folate supplements — an uncontrolled substitution that raised safety concerns among clinicians [9].

The Retracted Study

The scientific foundation for leucovorin's use in autism was already thin. Only five randomized clinical trials had ever tested oral folinic acid (leucovorin's active form) in autistic patients. Then, in February 2026, the largest of those studies was retracted [10].

The study, published in the European Journal of Pediatrics in September 2024, followed 77 autistic children over 24 weeks. Led by Dr. Prateek Kumar Panda of the All India Institute of Medical Sciences, it claimed that daily oral folinic acid significantly reduced symptom severity compared to a placebo, citing a P<0.001 significance level [10].

The unraveling began when Thomas Challman and Scott Myers, pediatricians at the Geisinger College of Health Sciences, noticed that the numbers in the published data tables did not add up. They posted their findings to PubPeer, a post-publication peer review platform, in September 2025 [10].

The journal's independent review "confirmed several of the concerns raised with the data and statistical analysis and was unable to replicate the results reported in the article from the dataset provided" [10]. Two of the six authors agreed with the retraction; four did not respond. Panda acknowledged "unintentional statistical analysis errors" and said a revised manuscript was being prepared [10].

With this retraction, only four small randomized trials remain — none of which provides robust evidence that leucovorin benefits the broader autism population.

The Science Behind the Split

To understand why the FDA drew such a sharp line between cerebral folate deficiency and autism, it helps to understand the underlying biology.

Cerebral folate transport deficiency is caused by mutations in the FOLR1 gene, which provides instructions for making folate receptor alpha — the protein responsible for transporting folate across the blood-brain barrier into the central nervous system [11]. When this receptor is broken, folate levels in cerebrospinal fluid plummet even as blood folate levels remain normal. The result is progressive neurological deterioration: developmental delays, seizures, movement disorders, and cognitive decline, typically appearing between ages two and three [11].

Leucovorin bypasses the broken receptor by providing 5-formyltetrahydrofolate (folinic acid) that can reach the brain through alternative transport mechanisms. When started early — ideally before age six — the treatment can produce substantial neurological improvement [11].

Autism, by contrast, is a complex neurodevelopmental condition with multiple genetic and environmental contributors. While some children with autism also have low cerebrospinal folate levels, the cause is typically not a FOLR1 mutation. Some researchers have investigated whether folate receptor autoantibodies — immune proteins that block the folate receptor — might contribute to a subset of autism cases, but this hypothesis remains unproven [12].

The symptoms of CFD-FOLR1 and autism do overlap — both can involve social communication challenges, sensory processing difficulties, and repetitive behaviors [6]. But overlapping symptoms do not mean overlapping mechanisms, and the FDA concluded that evidence supporting leucovorin worked only for the mechanistically clear case of FOLR1 mutations.

A Precedent-Setting Pathway — With Caveats

The FDA's decision to approve leucovorin based on published case reports rather than prospective clinical trials is noteworthy but not without precedent. The agency has accepted real-world evidence for ultra-rare diseases before — notably approving Brineura (cerliponase alfa) for Batten disease in 2017 using natural history controls, and onasemnogene abeparvovec for spinal muscular atrophy based on comparisons with natural history data [4].

What is unusual is the FDA's proactive role in this case. The agency itself reached out to GSK, the holder of the Wellcovorin brand, and asked the company to submit case report data the FDA had identified to enable a label update [3]. GSK, which had long since discontinued manufacturing Wellcovorin, complied — but made clear it would not resume production. The approval applies to all generic leucovorin versions already on the market [3].

For the roughly 330 Americans estimated to have the condition [1], this means the first formally approved treatment pathway — even if, in practice, many were likely already receiving leucovorin off-label.

The Broader Rare Disease Landscape

The leucovorin approval arrives amid a broader trend of increasing regulatory attention to rare diseases. In 2025, CDER approved 46 novel drugs, with 23 receiving Orphan Drug Designation for rare diseases — roughly half of all approvals [13]. This continues a pattern: orphan drugs represented 47% of novel therapies in 2024, 49% in 2023, and approximately 52% of all novel products approved between 2018 and 2023 [13].

Source: FDA CDER / RAPS

Data as of Jan 15, 2026CSV

Yet the scale of unmet need remains staggering. There are an estimated 7,000 to 10,000 rare diseases, and only about 5% have an FDA-approved treatment [13]. For the vast majority of rare disease patients, the path from diagnosis to therapy remains long, uncertain, and often nonexistent.

What It Means for Families

For the families of the fewer than 50 people worldwide with confirmed FOLR1-related cerebral folate deficiency, the approval provides formal medical recognition and a clearer treatment pathway. For the millions of families affected by autism, the FDA's decision is a sobering correction to premature political promises.

"There is no evidence to say that leucovorin will help most people with autism, and there's certainly no evidence to say it's safe," said Dr. Alycia Halladay of the Autism Science Foundation [8].

Doctors remain free to prescribe leucovorin off-label for autism — and many will likely continue to do so. But the FDA's refusal to endorse that use sends a clear regulatory signal that the evidence is not there yet.

The American Academy of Pediatrics has issued guidance urging clinicians to exercise caution, noting the limited and conflicting evidence base [12]. Ongoing clinical trials may eventually provide more definitive answers, though senior FDA officials indicated that early results from those trials are "not promising" [6].

The Cost of Mixed Messages

Perhaps the most consequential aspect of this story is not the drug approval itself but the public health communication failure that preceded it. A presidential announcement in September 2025 created expectations that the FDA could not fulfill six months later. In the interim, prescriptions surged, shortages developed, cancer patients lost access to a critical medication, and families of autistic children were left navigating confusing and contradictory signals from their own government.

The leucovorin episode illustrates a recurring tension in health policy: the gap between the pace of political messaging and the pace of scientific evidence. For rare disease patients, the approval is a genuine advance. For the broader autism community, it is a reminder that hope is not a substitute for data — and that the path to legitimate treatments requires patience, rigor, and honesty about what the evidence actually shows.